Company profile for Lipella Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Lipella is a privately-held biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma. Our lead product, LP-10 (liposomal tacrolimus) is in clinical development for the treatment of hemorrhagic cystitis. We maintain a pipeline of additional product candidates consistent with ...
Lipella is a privately-held biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma. Our lead product, LP-10 (liposomal tacrolimus) is in clinical development for the treatment of hemorrhagic cystitis. We maintain a pipeline of additional product candidates consistent with our strategy of developing proprietary 505(b)(2) assets that address highly-morbid indications where no adequate treatment(s) exists. A partial list of these assets is as follows.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
7800 Susquehanna St, Suite 505 Pittsburgh, PA 15208
Telephone
Telephone
1-412-894-1853
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/18/3152357/0/en/Lipella-Pharmaceuticals-Announces-Positive-Final-Results-from-Phase-2a-Study-of-LP-10-in-Oral-Lichen-Planus.html

GLOBENEWSWIRE
18 Sep 2025

https://www.prnewswire.com/news-releases/lipella-pharmaceuticals-to-present-at-zacks-scr-life-sciences-virtual-investor-forum-and-report-final-phase-2a-results-in-oral-lichen-planus-302555853.html

PR NEWSWIRE
15 Sep 2025

https://www.globenewswire.com/news-release/2025/06/25/3105404/0/en/Lipella-Pharmaceuticals-Issues-Letter-from-the-CEO-to-Stockholders-Following-Nasdaq-Delisting.html

GLOBENEWSWIRE
25 Jun 2025

https://www.globenewswire.com/news-release/2025/06/20/3102906/0/en/Lipella-Pharmaceuticals-Announces-Delisting-from-Nasdaq-Capital-Market.html

GLOBENEWSWIRE
20 Jun 2025

https://www.globenewswire.com/news-release/2025/06/17/3100642/0/en/Lipella-Pharmaceuticals-Announces-U-S-Patent-Issuance-for-Diagnostic-Technology.html

GLOBENEWSWIRE
17 Jun 2025

https://www.globenewswire.com/news-release/2025/06/04/3093548/0/en/Lipella-Pharmaceuticals-Re-signs-Manufacturing-Collaboration-Agreement-with-Cook-MyoSite-to-Support-LP-310-Clinical-Development.html

GLOBENEWSWIRE
04 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty